The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3792-3801

  Tzukerman, Maty ^a,b   Rosenberg, Tzur ^a   Reiter, Irena ^a   Ben Eliezer, Shoshana ^a   Denkberg, Galit ^a   Coleman, Raymond ^a   Reiter, Yoram ^a   Skorecki, Karl ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD VESSEL; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TERATOMA; TUMOR GROWTH; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL COMMUNICATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EMBRYO; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; MICE; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; TERATOMA; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645739220     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3467     Document Type: Article

References (44)

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
2. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001;1157-104.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
5. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
6. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
7. Geho DH, Bandle RW, Clair T, Liotta LA. Physiological mechanisms of tumor-cell invasion and migration. Physiology 2005;20:194-200.
8. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
9. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101:4966-71.
10. Rangarajan A, Weinberg RA. Comparative biology of mouse versus human cells: modeling human cancer in mice. Nat Rev Cancer 2003;3:952-9.
11. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905.
12. Wylie S, MacDonald IC, Varghese HJ, et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 1999;17:111-7.
13. Goldshmidt O, Zcharia E, Abramovitch R, et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002;99:10031-6.
14. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-90.
15. Folkman J. A novel anti-vascular therapy for cancer. Cancer Biol Ther 2004;3:338-9.
16. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9:2-10.
17. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
18. Chen H, Ikeda U, Shimpo M, et al. Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. J Cardiovasc Pharmacol 2000;36:498-502.
19. Pietersz GA, Wenjun L, Sutton VR, et al. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody. Cancer Immunol Immunother 1995;41:53-60.
20. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4241-4s.
21. Sordella R. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
22. Tzukerman M, Rosenberg T, Ravel Y, Reiter I, Coleman R, Skorecki K. An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2003;100:13507-12.
23. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7.
24. Pera MF, Reubinoff B, Trounson A. Human embryonic stem cells. J Cell Sci 2000;113:5-10.
25. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A 1991;88:8616-20.
26. Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 1994;54:2714-8.
27. Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000;15:271-8.
28. Tzukerman M, Shachaf C, Ravel Y, et al. Identification of a novel transcription factor binding element involved in the regulation by differentiation of the human telomerase (hTERT) promoter. Mol Biol Cell 2000;11:381-91.
29. Yalon M, Gal S, Segev Y, Selig S, Skorecki KL. Sister chromatid separation at human telomeric regions. J Cell Sci 2004;117:1961-70.
30. Zur A, Brandeis M. Timing of APC/C substrate degradation is determined by fzy/fzr specificity of destruction boxes. EMBO J 2002;2:4500-10.
31. Simmen FA, Gope ML, Schulz TZ, Wright DA, Carpenter G, O'Malley BW. Isolation of an evolutionarily conserved epidermal growth factor receptor cDNA from human A431 carcinoma cells. Biochem Biophys Res Commun 1984;15:125-32.
32. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;6:15-8.
33. George DJ, Kaelin WG, Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349:419-21.
34. Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A 2003;100:12741-6.
35. Gerecht-Nir S, Ziskind A, Cohen S, Itskovitz-Eldor J. Human embryonic stem cells as an in vitro model for human vascular development and the induction of vascular differentiation. Lab Invest 2003;83:1811-20.
36. Gerecht-Nir S, Osenberg S, Nevo O, Ziskind A, Coleman R, Itskovitz-Eldor J. Vascular development in early human embryos and in teratoma derived from human embryonic stem cells. Biol Reprod 2004;71:2029-36.
37. Gertow K, Wolbank S, Rozell B, et al. Organized development from human embryonic stem cells after injection into immunodeficient mice. Stem Cells Dev 2004;13:421-35.
38. Rossant J, Howard L. Signaling pathways in vascular development. Annu Rev Cell Dev Biol 2002;18:541-73.
39. Cleaver O, Melton DA. Endothelial signaling during development. Nat Med 2003;9:661-8.
40. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52.
41. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3:11-21.
42. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998;16:513-20.
43. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
44. Micke P, Tman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anticancer therapy? Lung Cancer 2004;45:S163-75.